The link between HSP90 inhibition and PI3K/AKT/mTOR signaling suppression has been previously reported in a number of solid and hematological malignancies, and our results support these findings (Basso et al., 2002; Ohji et al., 2006; Giulino-Roth et al., 2017). Here, HSP90AB1 is linked to hematologic disorder.